Company Overview of Cambrex Bio Science Walkersville, Inc.
Cambrex Bio Science Walkersville, Inc. engages in the manufacture and marketing of adult stem cell products for the life science research market. Its products include serum-free liquid media, micronized powdered medium, cell cultures, endotoxin detection products, Limulus Amebocyte Lysate products, sera, reagents, human cell systems, research and therapeutic media, electrophoresis, and chromatography products. The company provides custom manufacturing and cell therapy services. It also supplies culture media for the production of human adult stem cells in therapeutic applications. In addition, it offers software and equipment. The company serves biotechnology, clinical, pharmaceutical, and r...
8830 Biggs Ford Road
Walkersville, MD 21793
Key Executives for Cambrex Bio Science Walkersville, Inc.
General Counsel and Corporate Secretary
Vice President - Regulatory Affairs
Compensation as of Fiscal Year 2014.
Cambrex Bio Science Walkersville, Inc. Key Developments
Lonza Walkersville and Hyglos Signs Mutually Beneficial Global Settlement Deal and Licensing Agreement
Mar 18 13
Lonza Walkersville and Hyglos have signed a mutually beneficial global settlement deal that includes a licensing agreement for endotoxin detection patents. According to the deal, Hyglos will leverage Lonza's patent-protected recombinant factor C technology in the production of endotoxin products.
As part of the settlement, Lonza will cancel a previously filed lawsuit against Hyglos.
Lonza Walkersville, Inc. Wins $6.9 Million Contract
Feb 20 13
The National Institutes of Health Center for Regenerative Medicine has awarded Lonza Walkersville, Inc. (Cambrex Bio Science Walkersville, Inc.) a contract to generate induced pluripotent stem cells (iPSCs) for research purposes. This is the second contract the NIH has awarded Lonza for the generation of induced pluripotent stem cells (iPSCs). The Lonza contract is a three year agreement with a value up to $6.9 million.
Cambrex Bio Science Walkersville, Inc. Receives Contract to Generate Clinical Grade iPSCs by National Institutes of Health Center for Regenerative Medicine
Oct 10 12
The National Institutes of Health Center for Regenerative Medicine has awarded Cambrex Bio Science Walkersville, Inc. a contract to generate induced pluripotent stem cells (iPSCs) under current Good Manufacturing Practices (cGMP). The production of clinical grade iPSCs is considered a critical component to realizing the therapeutic potential of pluripotent stem cells. The contract also includes manufacturing of clinical grade iPSC-derived cell types.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|